Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| cbdMD, Inc.YCBD · Entity 8230 | President | May 16, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
cbdMD, Inc.
Report date May 16, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 20:06 UTC | cbdMD, Inc. YCBD · Entity 8230 | GrantCommon Stock (Right to Buy) · Derivative | 405,000 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001654954-22-007147 · section16.xml · derivative · entry 2 MacDermott Kevin · CIK 0001928755 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,000 Underlying: Common Stock · 405,000 shares Expires 2022-05-16 F2 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025. F2 · price: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025. F2 · derivative.exercise_date: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | cbdMD, Inc. YCBD · Entity 8230 | GrantCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-007147 · section16.xml · nonDerivative · entry 1 MacDermott Kevin · CIK 0001928755 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022. F1 · price: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.